Methods and Compositions Comprising Purified Recombinant Polypeptides

Genentech, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 7 of these applications claim priority to application PCT/US2014/055387, filed Sep 12, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 9,920,120	Methods and Compositions Comprising Purified Recombinant Polypeptides Genentech, Inc. In force Term ends Sep 12, 2034 · High confidence	Genentech, Inc.	In force	Term ends Sep 12, 2034	Term ends Sep 12, 2034	High confidence
US 10,597,446	Method of Treatment Comprising Purified Recombinant IL-13 Antibody Genentech, Inc. In force Term ends Sep 12, 2034 · High confidence	Genentech, Inc.	In force	Term ends Sep 12, 2034	Term ends Sep 12, 2034	High confidence
US 10,822,404	Methods and Compositions Comprising Purified Recombinant Polypeptides Genentech, Inc. In force Ends no later than Oct 8, 2034 · Medium confidence	Genentech, Inc.	In force	Ends no later than Oct 8, 2034	Ends no later than Oct 8, 2034	Medium confidence
US 11,667,706	Methods of Purifying Recombinant Anti-Abeta Antibodies Genentech, Inc. In force Term ends Oct 8, 2034 · Medium confidence	Genentech, Inc.	In force	Term ends Oct 8, 2034	Term ends Oct 8, 2034	Medium confidence
US 10,597,447	Compositions Comprising Purified Recombinant IL-13 Antibody Genentech, Inc. In force Term ends Nov 9, 2034 · High confidence	Genentech, Inc.	In force	Term ends Nov 9, 2034	Term ends Nov 9, 2034	High confidence
US 12,312,399	Methods and Compositions Comprising Purified Recombinant Polypeptides Genentech, Inc. In force Term ends Nov 9, 2034 · High confidence	Genentech, Inc.	In force	Term ends Nov 9, 2034	Term ends Nov 9, 2034	High confidence
US 10,494,429	Compositions Comprising Purified Anti-Abeta Monoclonal Antibodies Genentech, Inc. In force Term ends Nov 21, 2034 · High confidence	Genentech, Inc.	In force	Term ends Nov 21, 2034	Term ends Nov 21, 2034	High confidence
Application 19/191,611	Methods and Compositions Comprising Purified Recombinant Polypeptides Genentech, Inc. Abandoned Abandoned Jul 18, 2026	Genentech, Inc.	Abandoned	Abandoned Jul 18, 2026	not computed
Application 19/701,287	Methods and Compositions Comprising Purified Recombinant Polypeptides Genentech, Inc. Pending Not granted	Genentech, Inc.	Pending	Not granted	not computed

9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

7 of these are in force and held by Genentech, Inc..

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.